Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial

Eitemau Tebyg

• The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial
  gan: Daneshi-Maskooni, Milad, et al.
  Cyhoeddwyd: (2017)
• Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial
  gan: Daneshi-Maskooni, Milad, et al.
  Cyhoeddwyd: (2018)
• Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial
  gan: Jazayeri-Tehrani, Seyed Ali, et al.
  Cyhoeddwyd: (2019)
• Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol
  gan: Jazayeri-Tehrani, Seyed Ali, et al.
  Cyhoeddwyd: (2017)
• The effect of cardamom supplementation on serum lipids, glycemic indices and blood pressure in overweight and obese pre-diabetic women: a randomized controlled trial
  gan: Fatemeh, Yaghooblou, et al.
  Cyhoeddwyd: (2017)